Differential aqueous and vitreous concentrations of moxifloxacin and ofloxacin after topical administration one hour before vitrectomy

被引:24
作者
Lai, Wico W.
Chu, Kai On
Chan, Kwok Ping
Choy, Kwong Wai
Wang, Chi Chiu
Tsang, Chi Wai
Pang, Chi Pui
机构
[1] Univ Hong Kong, LKS Fac Med, Pokfulam, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Kowloon, Hong Kong, Peoples R China
[3] Chinese Univ Hong Kong, Dept Obstet & Gynecol, Kowloon, Hong Kong, Peoples R China
关键词
D O I
10.1016/j.ajo.2007.03.036
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE: To investigate the penetration of ofloxacin and moxifloxacin into the aqueous and vitreous after topical administration one hour before vitrectomy surgery. DESIGN: Prospective, randomized, double,blind case series study. METHODS: Twenty-seven patients undergoing vitrectomy were randomized to receive either topical ofloxacin 0.3% or moxifloxacin 0.5% every 10 minutes for one hour before surgery. Aqueous and vitreous samples were obtained and analyzed using high-performance liquidation chromatography. RESULTS: The moxifloxacin aqueous (1.576 +/- 0.745 mu g/ml) and vitreous (0.225 +/- 0.013 mu g/ml) levels were significantly higher than the ofloxacin aqueous (0.816 +/- 0.504 mu g/ml) (P =.0009) and vitreous (0.225 +/- 0.013 mu g/ml) [P=.0054] levels, respectively. The mean moxifloxacin aqueous and vitreous levels exceeded the minimum inhibitory concentration for 90% of isolates (MIC90) for a wide variety of bacteria implicated in endophthalmitis. In contrast, the aqueous level of ofloxacin exceeded the MIC90 of only a few organisms. CONCLUSIONS: Moxifloxacin applied every 10 minutes during the hour before vitrectomy penetrated the eye significantly better than ofloxacin.
引用
收藏
页码:315 / 318
页数:4
相关论文
共 7 条
[1]   Bacterial endophthalmitis prophylaxis for cataract surgery -: An evidence-based update [J].
Ciulla, TA ;
Starr, MB ;
Masket, S .
OPHTHALMOLOGY, 2002, 109 (01) :13-24
[2]   Vitreous penetration of topical moxifloxacin and gatifloxacin in humans [J].
Costello, Patrick ;
Bakri, Sophie J. ;
Beer, Paul M. ;
Singh, Ravinder J. ;
Falk, Naomi S. ;
Peters, George B. ;
Melendez, J. Andre .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2006, 26 (02) :191-195
[3]   Acute endophthalmitis. in eyes treated prophylactically with gatifloxacin and moxifloxacin [J].
Deramo, Vincent A. ;
Lai, James C. ;
Fastenberg, David M. ;
Udell, Ira J. .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2006, 142 (05) :721-725
[4]   Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous [J].
Hariprasad, SM ;
Blinder, KJ ;
Shah, GK ;
Apte, RS ;
Rosenblatt, B ;
Holekamp, NM ;
Thomas, MA ;
Mieler, WF ;
Chi, JD ;
Prince, RA .
ARCHIVES OF OPHTHALMOLOGY, 2005, 123 (01) :39-44
[5]   Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans [J].
Robertson, SM ;
Curtis, MA ;
Schlech, BA ;
Rusinko, A ;
Owen, GR ;
Dembinska, O ;
Liao, J ;
Dahlin, DC .
SURVEY OF OPHTHALMOLOGY, 2005, 50 :S32-S45
[6]   In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone [J].
Stroman, DW ;
Dajcs, JJ ;
Cupp, GA ;
Schlech, BA .
SURVEY OF OPHTHALMOLOGY, 2005, 50 :S16-S31
[7]   Vitreous and aqueous penetration of orally administered moxifloxacin in humans [J].
Vedantham, V. ;
Lalitha, P. ;
Velpandian, T. ;
Ghose, S. ;
Mahalakshmi, R. ;
Ramasamy, K. .
EYE, 2006, 20 (11) :1273-1278